ATrial Tachycardia PAcing Therapy in Congenital Heart
Congenital heart disease (CHD) affects approximately 1% of newborns in the US, with 25% of those affected having critical conditions requiring open heart surgery within one year of birth. Surgical and medical advances have allowed many patients to live beyond their fourth and fifth decades of life. Unfortunately, cardi
| Condition(s) | Atrial Arrhythmia, Atrial Tachycardia, Congenital Heart Disease, Pacemaker Re-Entrant Tachycardia |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Congenital heart disease (CHD) affects approximately 1% of newborns in the US, with 25% of those affected having critical conditions requiring open heart surgery within one year of birth. Surgical and medical advances have allowed many patients to live beyond their fourth and fifth decades of life. Unfortunately, cardiac arrhythmias are a relatively common sequela due to cardiac anomalies and surgical scars in addition to residual volume and pressure load on the heart. Atrial arrhythmias, including sinus node dysfunction and intra-atrial re-entrant tachycardia (IART) are among the more common abnormalities found in adults with repaired CHD. The presence of IART significantly increases morbidity and mortality, and anti-arrhythmic medications have been shown to be a sub-optimal treatment str |
| Who can participate | Inclusion Criteria: * must have structural CHD, an atrial arrhythmia and an ATD implanted. ATP must be turned on. Exclusion Criteria: * Other arrhythmias substrates such as Long QT (LQT), hypertrophic Cardiomyopathy (HCM), Catecholaminergic polymorphic ventricular tachycardia (CPVT), Arrhythmogenic Right Ventricular Cardiomyopathy.(ARVC), Brugada \& patients who undergo transplant, surgical maze, or ablation within 5 years of ATD implantation. |
| Sex | All |
| Lead sponsor | Ian Law |
| Locations | Los Angeles, California, United States; Orange, California, United States; Hollywood, Florida, United States; Indianapolis, Indiana, United States; Iowa City, Iowa, United States; Louisville, Kentucky, United States (+9 more sites) |
| Start date | 2018-09-01 |
| NCT ID | NCT03209583 |
| Official listing | https://clinicaltrials.gov/study/NCT03209583 |